The new Kodak Snapic A1 costs twice as much as other analog point-and-shoots. But I'm not sure it offers twice the quality.
Dealbreaker on MSN
Aktis has first biotech IPO of 2026, raising $318M to expand the reach of radiopharmaceuticals
Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted ...
Saturday is the last day Bavette La Boucherie, one of Milwaukee’s top restaurants for more than a decade, will be open for ...
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
TAIPEI, TW, Jan 12, 2026 - (ACN Newswire) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based ...
Lawmakers demand a range of actions, from a full investigation and policy changes to impeachment of the Homeland Security ...
President Donald Trump says Iran reached out to the U.S. and proposed negotiations after he threatened action in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback